Erasca (ERAS) Research & Development (2020 - 2026)
Erasca (ERAS) posted Research & Development of $27.3 million for Q1 2026, up 17.31% on a QoQ basis from $23.2 million in Q4 2025, and up 4.99% year-over-year from $26.0 million in Q1 2025.
Erasca (ERAS) Research & Development (2020 - 2026) Analysis & Trends
Erasca's Research & Development history runs 7 years deep, the most recent figure standing at $27.3 million for Q1 2026.
- Quarterly Research & Development rose 4.99% year-over-year to $27.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $94.1 million (down 16.5% YoY) and the FY2025 annual result came in at $92.9 million, down 19.51% from the prior year.
- Research & Development was $27.3 million for Q1 2026 at Erasca, up from $23.2 million in the prior quarter.
- Across five years, Research & Development topped out at $33.0 million in Q2 2024 and bottomed at $21.2 million in Q2 2025.
- A 5-year average of $26.6 million and a median of $27.3 million in 2026 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development jumped 124.0% — and 2025, when it tumbled 35.91%.
- Erasca's Research & Development stood at $29.4 million in 2022, then retreated by 15.5% to $24.8 million in 2023, then climbed by 5.31% to $26.1 million in 2024, then decreased by 11.03% to $23.2 million in 2025, then rose by 17.31% to $27.3 million in 2026.
- Business Quant data shows ERAS's Research & Development at $27.3 million in Q1 2026, $23.2 million in Q4 2025, and $22.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Erasca | 5.89 Bn | 5.89 Bn | - | 27.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.27 Mn |
| Dec 31, 2025 | 23.24 Mn |
| Sep 30, 2025 | 22.47 Mn |
| Jun 30, 2025 | 21.17 Mn |
| Mar 31, 2025 | 25.97 Mn |
| Dec 31, 2024 | 26.12 Mn |
| Sep 30, 2024 | 27.63 Mn |
| Jun 30, 2024 | 33.03 Mn |
| Mar 31, 2024 | 28.57 Mn |
| Dec 31, 2023 | 24.81 Mn |
| Sep 30, 2023 | 25.21 Mn |
| Jun 30, 2023 | 26.22 Mn |
| Mar 31, 2023 | 27.59 Mn |
| Dec 31, 2022 | 29.36 Mn |
| Sep 30, 2022 | 28.18 Mn |
| Jun 30, 2022 | 27.49 Mn |
| Mar 31, 2022 | 27.43 Mn |
| Dec 31, 2021 | 24.13 Mn |
| Sep 30, 2021 | 19.95 Mn |
| Jun 30, 2021 | 17.60 Mn |